Titus J. Boggon

Titus J. Boggon

Auto-generated profile, based on publicly available information

Titus J. Boggon

Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AKAmit Kumar
Amit Kumar
EPEdward Petri
Edward Petri
BHBalazs Halmos
Balazs Halmos
TBTitus J. Boggon
Titus J. Boggon
Purpose: To review the recent advances in the atomic-level understanding of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK). We aim to highlight the current and future importance of these studies for the understanding and treatment of malignancies where EGFR-TK is improperly activated. Methods: The analysis was conducted on published crystal structures deposited in the Protein Data Bank ( www.pdb.org ) using the program O. Results: In this review we emphasize how recent EGFR kinase domain crystal structures can explain the mechanisms of activation for L858R and other EGFR-TK mutations, and compare these distinct activating mechanisms with those recently described for the wild-type EGFR. We suggest an atomic-level mechanism for the poor efficacy of lapatinib against tumors with activating EGFR kinase domain point mutations compared with the efficacy of gefitinib and erlotinib, and demonstrate how structural insights help our understanding of acquired resistance to these agents. We also highlight how these new molecular-level structural data are expected to affect the development of EGFR-TK targeted small molecule kinase inhibitors. Conclusion: There are now more crystal structures published for the EGFR-TK domain than for any other TK. This wealth of crystallographic information is beginning to describe the mechanisms by which proper regulation of EGFR-TK is lost in disease. These crystal structures are beginning to show how small molecules inhibit EGFR-TK activity and will aid development of EGFR-TK mutant targeted therapies.

2 January 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MDMatthew J. Davis
Matthew J. Davis
BHByung Hak Ha
Byung Hak Ha
EHEdna C. Holman
Edna C. Holman
RHRuth Halaban
Ruth Halaban
JSJoseph Schlessinger
Joseph Schlessinger
TBTitus J. Boggon
Titus J. Boggon
RAC1 is a small, Ras-related GTPase that was recently reported to harbor a recurrent UV-induced signature mutation in melanoma, resulting in substitution of P29 to serine (RAC1 P29S ), ranking this the third most frequently occurring gain-of-function mutation in melanoma. Although the Ras family GTPases are mutated in about 30% of all cancers, mutations in the Rho family GTPases have rarely been observed. In this study, we demonstrate that unlike oncogenic Ras proteins, which are primarily activated by mutations that eliminate GTPase activity, the activated melanoma RAC1 P29S protein maintains intrinsic GTP hydrolysis and is spontaneously activated by substantially increased inherent GDP/GTP nucleotide exchange. Determination and comparison of crystal structures for activated RAC1 GTPases suggest that RAC1 F28L —a known spontaneously activated RAC1 mutant—and RAC1 P29S are self-activated in distinct fashions. Moreover, the mechanism of RAC1 P29S and RAC1 F28L activation differs from the common oncogenic mutations found in Ras-like GTPases that abrogate GTP hydrolysis. The melanoma RAC1 P29S gain-of-function point mutation therefore represents a previously undescribed class of cancer-related GTPase activity.

21 September 2017 in Blood
Verified
Journal Article
Closed access
PDF file
JPJoonhee Park
Joonhee Park
JYJingyi Yang
Jingyi Yang
AWAlexander T. Wenzel
Alexander T. Wenzel
ARAkshaya Ramachandran
Akshaya Ramachandran
WLWung J. Lee
Wung J. Lee
JCJaehyuk Choi
Jaehyuk Choi
Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell. In early-stage disease, lesions are limited to the skin, but in later-stage disease, the tumor cells can escape into the blood, the lymph nodes, and at times the visceral organs. To clarify the genomic basis of CTCL, we performed genomic analysis of 220 CTCLs. Our analyses identify 55 putative driver genes, including 17 genes not previously implicated in CTCL. These novel mutations are predicted to affect chromatin (BCOR, KDM6A, SMARCB1, TRRAP), immune surveillance (CD58, RFXAP), MAPK signaling (MAP2K1, NF1), NF-κB signaling (PRKCB, CSNK1A1), PI-3-kinase signaling (PIK3R1, VAV1), RHOA/cytoskeleton remodeling (ARHGEF3), RNA splicing (U2AF1), T-cell receptor signaling (PTPRN2, RLTPR), and T-cell differentiation (RARA). Our analyses identify recurrent mutations in 4 genes not previously identified in cancer. These include CK1α (encoded by CSNK1A1) (p.S27F; p.S27C), PTPRN2 (p.G526E), RARA (p.G303S), and RLTPR (p.Q575E). Last, we functionally validate CSNK1A1 and RLTPR as putative oncogenes. RLTPR encodes a recently described scaffolding protein in the T-cell receptor signaling pathway. We show that RLTPR (p.Q575E) increases binding of RLTPR to downstream components of the NF-κB signaling pathway, selectively upregulates the NF-κB pathway in activated T cells, and ultimately augments T-cell-receptor-dependent production of interleukin 2 by 34-fold. Collectively, our analysis provides novel insights into CTCL pathogenesis and elucidates the landscape of potentially targetable gene mutations. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Genomic analysis of 220 CTCLs identifies 55 genes in lymphomagenesis, including 17 genes not previously implicated in CTCL. RLTPR (p.Q575E) is a novel gain-of-function mutation that potentiates T-cell receptor signaling via selective upregulation of the NF-κB pathway.

3 May 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
EPEdward Petri
Edward Petri
AĆAndjelka Ćelić
Andjelka Ćelić
SKScott D. Kennedy
Scott D. Kennedy
BEBarbara E. Ehrlich
Barbara E. Ehrlich
TBTitus J. Boggon
Titus J. Boggon
MHMichael E. Hodsdon
Michael E. Hodsdon
The C-terminal cytoplasmic tail of polycystin-2 (PC2/TRPP2), a Ca 2+ -permeable channel, is frequently mutated or truncated in autosomal dominant polycystic kidney disease. We have previously shown that this tail consists of three functional regions: an EF-hand domain (PC2-EF, 720–797), a flexible linker (798–827), and an oligomeric coiled coil domain (828–895). We found that PC2-EF binds Ca 2+ at a single site and undergoes Ca 2+ -dependent conformational changes, suggesting it is an essential element of Ca 2+ -sensitive regulation of PC2 activity. Here we describe the NMR structure and dynamics of Ca 2+ -bound PC2-EF. Human PC2-EF contains a divergent non-Ca 2+ -binding helix-loop-helix (HLH) motif packed against a canonical Ca 2+ -binding EF-hand motif. This HLH motif may have evolved from a canonical EF-hand found in invertebrate PC2 homologs. Temperature-dependent steady-state NOE experiments and NMR R 1 and R 2 relaxation rates correlate with increased molecular motion in the EF-hand, possibly due to exchange between apo and Ca 2+ -bound states, consistent with a role for PC2-EF as a Ca 2+ -sensitive regulator. Structure-based sequence conservation analysis reveals a conserved hydrophobic surface in the same region, which may mediate Ca 2+ -dependent protein interactions. We propose that Ca 2+ -sensing by PC2-EF is responsible for the cooperative nature of PC2 channel activation and inhibition. Based on our results, we present a mechanism of regulation of the Ca 2+ dependence of PC2 channel activity by PC2-EF.

1 May 2016 in Molecular Cell
Verified
Journal Article
Closed access
SHStephanie Hamill
Stephanie Hamill
HLHua Jane Lou
Hua Jane Lou
BTBenjamin E. Turk
Benjamin E. Turk
TBTitus J. Boggon
Titus J. Boggon

3 August 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
OFOriana S. Fisher
Oriana S. Fisher
HDHanqiang Deng
Hanqiang Deng
DLDou Liu
Dou Liu
YZYa Zhang
Ya Zhang
RWRong Wei
Rong Wei
BSBing Su
Bing Su
Cerebral cavernous malformations 2 (CCM2) loss is associated with the familial form of CCM disease. The protein kinase MEKK3 (MAP3K3) is essential for embryonic angiogenesis in mice and interacts physically with CCM2, but how this interaction is mediated and its relevance to cerebral vasculature are unknown. Here we report that Mekk3 plays an intrinsic role in embryonic vascular development. Inducible endothelial Mekk3 knockout in neonatal mice is lethal due to multiple intracranial haemorrhages and brain blood vessels leakage. We discover direct interaction between CCM2 harmonin homology domain (HHD) and the N terminus of MEKK3, and determine a 2.35 Å cocrystal structure. We find Mekk3 deficiency impairs neurovascular integrity, which is partially dependent on Rho–ROCK signalling, and that disruption of MEKK3:CCM2 interaction leads to similar neurovascular leakage. We conclude that CCM2:MEKK3-mediated regulation of Rho signalling is required for maintenance of neurovascular integrity, unravelling a mechanism by which CCM2 loss leads to disease.